Connor, Clark & Lunn Investment Management (CC&L)’s Teva Pharmaceuticals TEVA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-823,544
| Closed | -$14.8M | – | 1634 |
|
|
2024
Q3 | $14.8M | Buy |
+823,544
| New | +$14.8M | 0.07% | 208 |
|
|
2023
Q2 | – | Sell |
-39,233
| Closed | -$347K | – | 1493 |
|
|
2023
Q1 | $347K | Sell |
39,233
-3,685
| -9% | -$32.6K | ﹤0.01% | 979 |
|
|
2022
Q4 | $391K | Buy |
+42,918
| New | +$391K | ﹤0.01% | 930 |
|
|
2021
Q2 | – | Sell |
-345,263
| Closed | -$3.98M | – | 1101 |
|
|
2021
Q1 | $3.98M | Sell |
345,263
-2,835,932
| -89% | -$32.7M | 0.02% | 408 |
|
|
2020
Q4 | $30.7M | Sell |
3,181,195
-182,881
| -5% | -$1.76M | 0.18% | 107 |
|
|
2020
Q3 | $30.3M | Buy |
3,364,076
+1,759,561
| +110% | +$15.9M | 0.2% | 102 |
|
|
2020
Q2 | $19.8M | Buy |
1,604,515
+1,087,898
| +211% | +$13.4M | 0.14% | 127 |
|
|
2020
Q1 | $4.64M | Buy |
+516,617
| New | +$4.64M | 0.04% | 265 |
|
|
2019
Q2 | – | Sell |
-838,120
| Closed | -$13.1M | – | 1068 |
|
|
2019
Q1 | $13.1M | Sell |
838,120
-1,373,412
| -62% | -$21.5M | 0.09% | 165 |
|
|
2018
Q4 | $34.1M | Buy |
2,211,532
+231,332
| +12% | +$3.57M | 0.23% | 82 |
|
|
2018
Q3 | $42.7M | Buy |
1,980,200
+72,875
| +4% | +$1.57M | 0.24% | 76 |
|
|
2018
Q2 | $46.4M | Sell |
1,907,325
-8,425
| -0.4% | -$205K | 0.26% | 69 |
|
|
2018
Q1 | $32.7M | Buy |
+1,915,750
| New | +$32.7M | 0.2% | 95 |
|